Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...

Full description

Bibliographic Details
Main Authors: Anne Clavreul, Emilie Roger, Milad Pourbaghi-Masouleh, Laurent Lemaire, Clément Tétaud, Philippe Menei
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Drug Delivery
Subjects:
drug delivery
glioblastoma
lipid nanocapsules
sorafenib
Online Access:http://dx.doi.org/10.1080/10717544.2018.1507061

Similar Items

Similar Items